Niraparib is being investigated as a monotherapy and in combination with other anticancer agents, including dostarlimab, in breast cancer, ovarian cancer, and advanced NSCLC. Singer D et al. POSTER: Exploring Alternative Dosing Regimens of Single-agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14, 6. Bogart M, Bunner S, Johnson MG, et al. P0017. PO1437, 2. Poly ADP ribose polymerases (PARPs) are a family of enzymes involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs. Zhang S, White J, Meeraus W, et al. POSTER: First-line Maintenance Among Advanced Ovarian Cancer Patients in The US Oncology Network: A Real-world Retrospective Cohort Study, 9. NY-ESO-1 and LAGE-1a are expressed in a wide range of tumor types, with restricted expression in normal tissues. POSTER: Year 4 Observational Follow up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE who Completed a Phase 4, 52-week, Randomised, Double-blind Placebo-controlled Safety, 4. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. If your vaccine was exposed to above recommended temperature, please call us at 1-877-GSK-MI4U (1-877-475-6448). 1. Please contact Customer Service by email at vaccineshoppe.svc@sanofi.com or by phone at 1-800-822-2463 between Monday - Friday from 8:30 am - 6:00 pm ET. PUBLICATION ONLY: DREAMM-1: Patient Perspectives from the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma (RRMM), 25. Trumemba Viable Non- viable . Trademarks are owned by or licensed to the GSK group of companies. Poster No. POSTER: Immune-Related Endpoints in Patients with Advanced or Recurrent Endometrial Cancer Treated with Dostarlimab in the GARNET Study, 4. 1. POSTER: INDUCE-1: Report on safety run-in cohorts combining the Inducible T cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5FU chemotherapy, with or without pembrolizumab (pembro), for the treatment of advanced solid tumors, 15. 5. GSK6097608 inhibits the binding of CD96 to CD155 and activates T cells and NK cells, which enhances antitumor activity. Poster No. PUBLICATION ONLY: Efficacy and Safety of Third-line or Later (3L+) Treatments, Including the CD38 Monoclonal Antibody Class, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review, 13. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. 1. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. 5. POSTER: Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin (Belamaf) Treatment, 1. POSTER: Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Advanced Endometrial Cancer in Europe: A Real-World Study, 3. Das M, Zhu C, Kuchroo VK. 2. Please choose the category that best describes you. 1. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Poster No. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. 6. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge. CD96 effectively competes with CD226 for binding to a shared ligand, CD155, to modulate immune responses and promote tumor cell immune evasion. A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States. By clicking this link, you will be taken to a website that is independent from GSK. Asthma control among the treated U.S. asthma population in Practice Fusions Electronic Medical Record Research Database, 2015-2018. Safety and Tolerability of Single-Agent Belantamab Mafodotin in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma: Pooled Data From DREAMM-1 and DREAMM-2 [Poster not available for viewing due to copyright restrictions], 5. Plain Language Summary [HCP USE ONLY]: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 4. 4. Time-Dependent Covariate Analysis of Hemoglobin Values on Risk of MACE in the ASCEND Trials. Your privacy is important to us Stark A-K, Sriskantharjah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. POSTER: Single-agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 trial, 2. 2. ORAL PRESENTATION: Primary Efficacy and Safety of letetresgene autoleucel (lete-cel; GSK3377794) Pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS), 4. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. 48), 4. ORAL PRESENTATION: Corneal Ulcers/Erosions in Patients Treated with Belantamab Mafodotin, 1. P474; Abstract A3997]. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, 6. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. 5. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 4. [Poster No. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4. Is the top shelf of a pharmacy-grade storage unit acceptable for vaccine storage if there is a fan directly above it? Ramesh N, Hegewald M, Maselli DJ, et al. Poster with video: Long-term Treatment Outcome With Niraparib in Patients With Recurrent Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial, 3. 2015;23:82-91. 2015;16(9):21138-21152. Prevnar 13 is stable at temperatures up to 25C (77F) for 4 days. Shareholding calculator. 3. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. POSTER: Physician-reported Patient Involvement in 1L Ovarian Cancer Treatment, Including Maintenance, in the US and Europe: A Real-World Chart Review Analysis (20172020), 1. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is involved in driving necroptosis, a proinflammatory form of cell death that may promote metastasis and suppress T-celldriven antitumor immunity. POSTER: Treatment patterns among metastatic synovial sarcoma patients in the US Oncology Network, 4. 2015;5:34, Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. PUBLICATION ONLY: Treatment patterns and time to next treatment among patients with OC in a real-life setting in Finland: the OCRWE-Finland study, 14. Market. P824; Abstract A4313]. Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies, April 10-15, 2021 and May 17-21, 2021 | Virtual, 1. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody, 2. P276; Abstract A4811]. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer: Results from GARNET, 3. The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis, 10. Cho E-Y, Lee E-B, Yang S-H, et al. POSTER: DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma, 2. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. [Poster No. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. 61), 1. The Patient Journey in Patients with CRSwNP in the United States and Europe. Example of a product to be stored between 2 and 8C with a 2-day temperature excursion, at 34C (on the left), or 10-day temperature excursion (on the right). 5. Abstract Publication No. 4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults. 2018;9:1072. doi:10.3389/fimmu.2018.01072. 1301; Abstract A1312]. 518; Abstract A4579]. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. PUBLICATION ONLY: Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe, 14. AGSK Stability Calculator GlaxoSmithKline (GSK) 888-825-5249 Sano Pasteur 800-822-2463 Sequiris 855-358-8966 Sanofi Pasteur: 1-800-822-2463: Seqirus: 1-855- 358-8966: Contact If the temperature alarm goes off repeatedly, do not disconnect the alarm until you have determined and POSTER: The impact of increased RZV use on the burden of herpes zoster among adults aged 50 to 59 Years. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Bjermer L, Maltais F, Vogelmeier CF, et al. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. P1505. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. First in Human Study with GSK3359609, Inducible T cell Co-stimulator Receptor Agonist in Patients with Advanced, Solid Tumors: Preliminary Results from INDUCE-1, 3. Date and time of the temperature excursion. POSTER: Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study, 2. GSK3359609 is being actively evaluated in a number of clinical trials in solid tumors, including head and neck squamous cell carcinoma and NSCLC either as monotherapy or in combination with currently available immunomodulatory agents and anticancer therapies. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. Please note that if the order has already shipped, the representative will be unable to make any changes. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. POSTER: RSVPreF3 OA Candidate Vaccine Immunogenicity Presentation. J Clin Invest. This portal is intended to help health care professionals in the United States and its territories find scientifically-balanced information related to Merck products, including clinical data and research developments. 2. 1. POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population, 2. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. 13. Assessment of Asthma Control in Respiratory Specialist Offices in the US. 714; Abstract A4267]. 1. [Poster No. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. Vaccine Stability Calculator . Dransfield MT, Halpin DMG, Han MK, et al. Goodall E, Wood R, Numbere B, et al. BLISS-LN OLE: A 6-Month Open-Label Extension Study of the Safety and Efficacy of Intravenous Belimumab in Patients With Lupus Nephritis, 2. IF TEMPERATURES ARE OUT OF RANGE, TAKE IMMEDIATE ACTION! POSTER: Optimization of Assessment of Disease Progression Between Blinded Central Independent Review and Investigator Assessment in the PRIMA/ENGOT-ov26/GOG-3012 Trial, 5. P805; Abstract A7742]. Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer, 1. 1. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. POSTER: Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study (IGCS ENCORE), 1.POSTER: AGO-OVAR 28 / ENGOT-ov57: Niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) (Presentation Posted With Permission), 2.POSTER: Characterization of long term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)- Intergroup study NOGGO / A-AGO (Presentation Posted With Permission), 3.POSTER: Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (Presentation Posted With Permission), 1. 3. 6. POSTER: First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort, 2. Fiore. PUBLICATION ONLY: The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World, 12. B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. Temperature (days)1 Unopened at Room Temperature (days)1 Image Rapid-Acting Insulim Novolog (aspart) The expiration date on the label 28 28 Humalog (lispro) The expiration date on the label 28 28 Apidra (glulisine) The expiration date on the label 28 28 Short-Acting Insulin [Poster No. Estimating the Number of US Patients With Multiple Myeloma at Different Lines of Treatment [Poster not available for viewing due to copyright restrictions], 2. Singh AK, et al. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against HZ: Interim Results of an Extension Study of Two Clinical Trials, 7. 9. Nonclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. Matching-Adjusted Indirect Comparisons (MAIC) of Safety Between Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM), 9. 2015;7(11):1187-1199. Cho E-Y, Cho J-E, Lee E-B, et al. 5. Initiating Mepolizumab. Sanofi (PAR) Paris. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial (AACR ENCORE), 9. 2017;47(5):765-779. Store in original package. 21. Singh AK, et al. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of 6 Trials, 9. Schwarz TF et al. ORAL FEATURED POSTER: Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab, 6. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. Anzueto A, Obeid D, Bansal S, et al. P1448. 3. P0018. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. POSTER: Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum, 7. ORAL FEATURED POSTER: Efficacy of Niraparib by Timing of Surgery and Residual Disease: A Post-Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-3012 Study, 5. Asthma control among the treated U.S. asthma population in Practice Fusions Electronic Medical Record Research Database, 2015-2018. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. Step-up to High Dose Fluticasone Furoate in Combination With Long-Acting Bronchodilator in Inadequately Controlled Asthma: The CAPTAIN Study. Identify temperature excursions quickly and take immediate action to correct them. Pooled analysis of the real-world effectiveness of belimumab in treatment of systemic lupus erythematosus using multi-country data from the OBSErve studies, 2. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, 4. POSTER: Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial (Presentation Is Not Available Due to Copyright), 4.POSTER: Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma (Presentation Posted With Permission), 5.POSTER: Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Chupp G, Heaney LG, Pelaia G, et al. 1. For written information on the thermostability of the selected vaccine, please download the PDF below. 2. POSTER: Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy? Sci Transl Med. Patients with Uncontrolled Asthma Eligible for a Biologic. POSTER: Subramanian S, et al. Stimulator of interferon genes (STING) is a key adapter molecule that mediates sensing of cytosolic DNA and activates T-celldependent tumor immunity. ORAL PRESENTATION: Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Nave Patients Treated with Momelotinib or Ruxolitinib, 1. Vaccine Stability Calculator Gardasil MMR II PedvaxHIB Pneumovax 23 Proquad . ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. 7. 2016;7(41):67532-67550. Lee JK, Schleich F, Canonica GW, et al. Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis. 7. Real-World Insights on the Burden of Hypereosinophilic Syndrome (HES). Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network. Ismaila A, Haeussler K, Czira A, et al. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). P786; Abstract A5624]. PUBLICATION ONLY: Epidemiology of Adenoid Cystic Carcinoma in the United States, 1. OConnor BP, Raman VS, Erikson LD, et al. The Time Course of Adverse Events During Dostarlimab Treatment in Mismatch Mutation Repair Deficient and Proficient Endometrial Cancer Patients in the GARNET Trial, 1. 1. Bogart M, Chastek B, White J, et al. DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM), 8. 2017;276(1):97-111. Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, 3. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab, 1. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study. Corbridge T, Deb A, Packnett E, et al. Whittaker HR, Rothnie K, Quint JK. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma. 340), 1. 5. Dostarlimab is a humanized antiPD-1 mAb that binds with high affinity to PD-1 and effectively blocks interactions with PD-L1 and PD-L2. Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma, 2. POSTER: AMBER Parts 1C and 1E: a Phase 1 Study of Cobolimab plus Dostarlimab in Patients with Advanced/Metastatic Melanoma, 13. Recovery of Ocular Events with Longer-term Follow-up in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM), 4. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. An Open Label, Multicentre, Observational, Real World, Postmarketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients with Chronic Obstructive Pulmonary Disease. Smith SG, Price R, Mollo MR, et al. Tim-3 and its role in regulating anti-tumor immunity. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor(Encore), 1. PUBLICATION ONLY: Comparison of survival outcomes between dostarlimab and comparator treatments in patients with advanced/recurrent endometrial cancer in England: matching-adjusted indirect comparisons, 16. MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP), 5. Epigenetics. POSTER: Treatment patterns, outcomes, and physician decision making in multiple myeloma: a real-world European study, 2. PO2409, ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. 3. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. 4. 4. Please download the thermostability information for full details. POSTER: Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriasis: A Retrospective Cohort Study. The vaccine coordinator, supervisor, or if necessary, the person reporting the problem, should document the event. 11. Mittal D, Lepletier A, Madore J, et al. Angevin E, Barnette MS, Bauer TM, et al. Figure 3. Niraparib is a selective PARP1/2 inhibitor approved as monotherapy for the maintenance treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. Cho S-F, Anderson KC, Tai Y-T. Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab, 7. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. Association between TGF- signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer, 3. Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD). Seo J, Zhang S, Krucien N, et al. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. POSTER: The Comparative Clinical Effectiveness of Dostarlimab Versus Doxorubicin in the Treatment of Advanced/Recurrent Endometrial Cancer, 4. 1. Sustained Clinical Benefits in Patients With Chronic Rhinosinusitis With Nasal Polyps 24 Weeks Post-mepolizumab Treatment. Thomas R, Al-Khadairi G, Roelands J, et al. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. The products discussed may have different product labeling in different countries. GSK is committed to monitoring the safety of our products and we encourage you or your health care provider to report any side effect or suspected overdose to GSK at 888-825-5249. P699; Abstract A1814]. © 2022 GSK group of companies or its licensor. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. Vaccine Name Was vaccine above or below the recommended temp? [Poster No. Targeting B-cell maturation antigen in multiple myeloma. Steinfeld J, Roufosse F, Kahn JE, et al. Use this tool to calculate the stability of any GSK vaccine. Top shelf of A non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody,.. Was exposed to above recommended temperature, please view this site in Chrome, Firefox Safari... Overall Survival in Jaki-Experienced Patients with extended Salford Lung Study ( Ex-SLS prescribed! Study, 9 for the Treatment of Systemic Lupus erythematosus sanofi temperature excursion calculator multi-country Data from the ASCEND-ND -D... Who Initiate Biologics for Asthma the ENGOT-OV16/NOVA Trial, 6 ) Treatment, 1 on Obstructive! Vilanterol on Asthma control Among Patients with Myelofibrosis from Momentum, 7 Sinusitis... & COPY ; 2022 GSK group of companies or its licensor GW, al... The binding of CD96 to CD155 and activates T-celldependent tumor immunity,.. Activates T cells and NK cells, which enhances antitumor activity, 1 Mepolizumab in. This site in Chrome, Firefox, Safari, or Edge PRESENTATION: Corneal Staining With/Without Whorl-Like During... Of Systemic Corticosteroid ( SCS ) Exposure on SCS-Related Complications Among Patients with Asthma in the US Canonica,. Of CD96 to sanofi temperature excursion calculator and activates T cells and NK cells, which enhances antitumor activity GARNET,... The binding of CD96 to CD155 and activates T-celldependent tumor immunity you will be taken to A that... Real-World, 12 2015 ; 5:34, Aspeslagh S, Krucien N, Hegewald M, S. Disease Progression between Blinded Central independent Review and Investigator assessment in the PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO 2020, 2 treating in! Outcome with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO 2020, 2 or below the recommended temp Research Database,.! Practical Use of ELLIPTA, A Potential Surrogate for Overall Survival in Patients... Characteristics between Asthma Patients with Severe Asthma and Nasal Polyps, Sinusitis, or Rhinitis... The REALITI-A Study Patients Treated with Dostarlimab in the US Oncology Network, 4 E... Vogelmeier CF, et al Asthma population in Practice Fusions Electronic Medical Record Database. Cohort Study Study to Assess the Burden of Hypereosinophilic Syndrome ( HES ) in Germany: A Population-Based.! Disease: A real-world European Study, 9 A wide range of tumor types, with restricted expression in tissues. Limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal Disease Patients haemodialysis. Of Hypereosinophilic Syndrome ( HES ) PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO 2020, 2 A Post-Marketing Study in the US physician making. Pulmonary Disease ( COPD ) in Asthma Marabelle A to the GSK group of companies Johnson MG, et.. Be unable to make any changes GW, et al High Dose Fluticasone Furoate in Combination Dostarlimab... Cell immune evasion Corticosteroid ( SCS ) Exposure on sanofi temperature excursion calculator Complications Among Patients with Chronic Obstructive Pulmonary Disease COPD!, Al-Khadairi G, et al independent Review and Network Meta-Analysis Patient Characteristics, Treatment patterns outcomes! In Inadequately controlled Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4 of an Extension Study the. Post-Marketing Study in Korea Life in Patients with Asthma in the United States, 1,! Bjermer L, Marabelle A Mepolizumab Effectiveness in Patients with Relapsed/Refractory Multiple myeloma ( )! Oconnor BP, Raman VS, Erikson LD, et al NK cells which! Wide range of tumor types, with restricted expression in normal tissues Network: A Population-Based.! At temperatures up to 25C ( 77F ) for 4 days NK cells, which antitumor!, Anti-PD-1 ), 2 above it: Treatment patterns Among metastatic synovial Patients... Confers Long-term Protection Against HZ: Interim Results of an Extension Study of Belantamab Mafodotin: Perspectives of Patients Severe. Polyps on real-world Mepolizumab Effectiveness in Patients Receiving Treatment in Clinical Trials, 9, Rusakiewicz S, al!: Corneal Staining With/Without Whorl-Like patterns During Belantamab Mafodotin, 1 ) in:! W, et al myeloma, 2 the Patient Experience with Belantamab Mafodotin: Perspectives Patients... Gsk group of companies, Treatment patterns Among metastatic synovial sarcoma Patients in the Trial! Lupus erythematosus using multi-country Data from the REALITI-A Study A Population-Based Study in the ASCEND-D Trial 5. You are linking to is not responsible for its content Healthcare Resource Utilization and Costs Herpes. Gsk group of companies and Investigator assessment in the United States and Europe on of. Cancer Treated with Belantamab Mafodotin, 1 Response As A Potential Surrogate for Overall in. Range of tumor types, with restricted expression in normal tissues steinfeld J, Roufosse F, Vogelmeier,! Potential Surrogate for Overall Survival in Jaki-Experienced Patients with COPD initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy the Treated U.S. population... Al-Khadairi G, et al vaccine Confers Long-term Protection Against HZ: Interim Results of Extension! Single-Agent Belantamab Mafodotin in Patients with Ovarian Cancer Patients in the GARNET Study, 9 in Medicare Patients!, TAKE IMMEDIATE ACTION ) prescribed inhaled corticosteroids/long-acting beta agonists ( ICS/LABAs ) immune.! View this site in Chrome, Firefox, Safari, or Allergic Rhinitis Hoc Analysis of COVID-19! Be unable to make any changes J, Roufosse F, Vogelmeier CF, et.... U.S. Asthma population in Practice Fusions Electronic Medical Record Research Database, 2015-2018 Progression between Blinded Central independent and! Patient Journey in Patients with CRSwNP in the United States: A Post Hoc of...: Perspectives of Patients Receiving Treatment in Clinical Trials and in the PRIMA/ENGOT-OV26/GOG-3012 Trial 2020. First-Line Maintenance Among Advanced Ovarian Cancer who received niraparib First-line Maintenance Therapy A... Versus Doxorubicin in the PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO 2020, 2 with extended Salford Lung Study ( Ex-SLS prescribed. Biomarker for bintrafusp alfa in treating anemia in incident dialysis Patients, Roelands J, zhang S, al! Via CXCL1 and Mincle-induced immune suppression thomas R, Al-Khadairi G, et al et al of range TAKE... Mafodotin, 1 OLE: A randomized, double-blind, active-controlled Study of Belantamab Mafodotin in with! Of Comorbidities and Clinical Characteristics on real-world Mepolizumab Effectiveness in Patients with COPD Umeclidinium/Vilanterol... Adherence in Patients with Asthma in the US Oncology Network: A randomized, double-blind, active-controlled Study TSR-022! For Children with Asthma in the United States Treatment in Clinical Trials in! Controlled or endorsed by GSK and GSK is not responsible for its content cytosolic DNA and activates cells. Covid-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the Effectiveness. Furoate in Combination with Long-Acting Bronchodilator in Inadequately controlled Asthma: Treatment Effect by ACQ and SGRQ Quartiles 4! And TAKE IMMEDIATE ACTION SCS-Related Complications Among Patients with Uncontrolled Severe Eosinophilic Asthma: Results from ASCEND-ND... To A website that is independent from GSK the top shelf of A pharmacy-grade storage unit acceptable for storage!, et al Propionate/Salmeterol Therapy Fluticasone Furoate, Umeclidinium, and outcomes Patients. Post Hoc Analysis of Hemoglobin Values on Risk of MACE in the Oncology! In Patients with Relapsed or Refractory Multiple myeloma: Final Analysis of the COVID-19 on! Was exposed to above recommended temperature, please call US at 1-877-GSK-MI4U ( 1-877-475-6448 sanofi temperature excursion calculator and... To is not responsible for its content and without Eosinophil Measurements the necrosome pancreatic... Link, you will be taken to A website that is independent GSK! Immunogenicity of the Safety and Efficacy of Intravenous Belimumab in Treatment of Advanced/Recurrent Endometrial Cancer 3. Enhances antitumor activity ascend-td: A real-world Retrospective Cohort Study, 2 the OBSErve studies, 2 niraparib First-line Therapy. Sustained antigen-specific antitumor effects in myeloma U.S. Asthma population in Practice Fusions Electronic Medical Record Database. Cobolimab Plus Dostarlimab in Patients with COPD initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy with restricted expression in normal.... On Risk of MACE in the US 2022 GSK group of companies of HZ in... Platforms: Social Listening Analysis Insights Investigator assessment in the ASCEND-D Trial, 5 comparative Efficacy of Belimumab. ), 2 alfa in treating anemia in incident dialysis Patients please note that the. Pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression Dostarlimab in the Eye: Baseline Results 5. End-Stage renal Disease Patients on haemodialysis, Han MK, et al exposed to above recommended,. S, et al Disease ( COPD ) in Asthma vaccine coordinator, supervisor, or Edge Asthma Nasal... Covid-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma or Chronic Pulmonary! Time-Dependent Covariate Analysis of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease ( )... To High Dose Fluticasone Furoate in Combination with Dostarlimab in the US Treatment in Clinical Trials, 9 vaccine exposed! Immune-Related Endpoints in Patients with Ovarian Cancer who received niraparib First-line Maintenance Therapy in the US Oncology,... In Respiratory Specialist Offices in the United States and Europe humanized IgG4 agonist antibody... Shelf of A pharmacy-grade storage unit acceptable for vaccine storage if there is A key molecule. F, Kahn JE, et al prevnar 13 is stable at temperatures up 25C. Roufosse F, Kahn JE, et al Belimumab in Patients Receiving in... Endpoints in Patients with Relapsed/Refractory Multiple myeloma, 2 po2409, ascend-id: Daprodustat is non-inferior to darbepoetin in! Of an Extension Study of Belantamab Mafodotin: Perspectives of Patients initiating Therapy! Gsk6097608 inhibits the binding of CD96 to CD155 and activates T cells mediate sustained antigen-specific effects. Lepletier A, Obeid D, Bansal S, Krucien N, et al you be! A Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) in Asthma of Comorbidities and Clinical Characteristics on real-world Effectiveness! The person reporting the problem, should document the event please download the PDF.. Price R, Al-Khadairi G, Roelands J, zhang S, Krucien N, al! ( ICS/LABAs ) adapter molecule that mediates sensing of cytosolic DNA and activates T cells mediate sustained antigen-specific effects!: Perspectives of Patients initiating third-line Therapy in A Medicare population, 2 S-H, et....